Newsroom | 1376 results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: UBS Global Healthcare Conference on Monday, November 10 at 11:00 AM Eastern Time Jefferies Global Healthcare Conference in London on Wednesday, November 19 at 2:00 PM Greenwich Mean Time Citi’s Global Healthcare Conference on Tuesday, December 2 at 11:15 AM Eastern Time Annual Evercore Healthcare Conference on Wednesday, December...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that the Company will participate in the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference (Fireside Chat) Wednesday, November 12 (11:30 a.m. ET) Jefferies Global Healthcare Conferenc...

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens has launched the 2025-2026 Respiratory Index, an interactive online tool that tracks flu and COVID-19 activity nationwide using prescription, testing and over the counter (OTC) product purchase data from Walgreens locations nationwide. This unique tool builds on more than a decade of insights from the Walgreens Flu Index to now offer a more comprehensive view of respiratory illness trends across the U.S., helping the public, healthcare providers, and...

NEW YORK--(BUSINESS WIRE)--CastleVax, a clinical-stage biotechnology company developing intranasal vaccines using its attenuated Newcastle Disease Virus (NDV)-based vaccine platform, announced today that the first participant has been dosed in a Phase 2 clinical study of CVAX-01, its intranasal, next-generation, COVID-19 vaccine candidate. The study is designed to evaluate the safety, tolerability and both systemic and mucosal immunogenicity of CVAX-01 against a U.S. Food and Drug Administratio...

MIAMI--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab, will cohost a webinar, “Equity on the Line: The PABS Annex and the Future of the Pandemic Agreement,” on Wednesday, October 29, 2025 at 10:00 AM EDT, virtually via Zoom. Register here. The Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement has entered a decisive phase, with Member States facing a compressed timeline to finalize the Pathogen Access a...

SAN FRANCISCO--(BUSINESS WIRE)--Omni, the business intelligence and embedded analytics platform with a built-in semantic layer, announced the acquisition of Explo, a leading embedded analytics company. The acquisition comes during a period of rapid growth for Omni, with projected annual recurring revenue (ARR) reaching $30 million by the end of 2025, representing 4x year-over-year growth after 10x growth in 2024. Omni expects to double ARR again in 2026, driven by growing demand for a unified a...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced interim results from its ongoing Phase 2 clinical trial of ARCT-032, an investigational inhaled mRNA therapy for people with cystic fibrosis. In the second cohort of the study, six Class I CF adults received inhaled 10 m...

KYIV, Ukraine--(BUSINESS WIRE)--Enamine, a leading chemistry and R&D services company, today announced that it was a key synthetic chemistry contributor to a first-of-its-kind, open-science approach that led to the development of a promising broad-spectrum coronavirus antiviral pre-clinical candidate. Enamine’s chemistry platform delivered over 2,000 new compounds during the early stages of the programme that resulted in the discovery of pre-clinical candidate ASAP-0017445. The candidate is...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases. “IDWeek 2025 offers a critical opportunity to highlight our cutting-edge scientific progress and collaborate with global health experts in our ongoin...

LONDON--(BUSINESS WIRE)--The Institute of Clinical Research (The ICR) is delighted to announce the launch of its Company Membership Scheme, an initiative designed to strengthen professional development and collaboration across the clinical research sector by increasing access to the clinical research community to a wider membership. Several organisations have already joined as Company Members, demonstrating strong interest in the scheme and its benefits for both organisations and individual mem...